Jobevne Dosage
Generic name: BEVACIZUMAB 25mg in 1mL
Dosage form: injection
Drug class: VEGF/VEGFR inhibitors
Medically reviewed by Drugs.com. Last updated on Apr 1, 2025.
Important Administration Information
Withhold for at least 28 days prior to elective surgery. Do not administer Jobevne until at least 28 days following major surgery and until adequate wound healing.
Metastatic Colorectal Cancer
The recommended dosage when Jobevne is administered in combination with intravenous fluorouracil-based chemotherapy is:
- •
- 5 mg/kg intravenously every 2 weeks in combination with bolus-IFL.
- •
- 10 mg/kg intravenously every 2 weeks in combination with FOLFOX4.
- •
- 5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks in combination with fluoropyrimidine-irinotecan-or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who have progressed on a first-line bevacizumab product-containing regimen.
First-Line Non-Squamous Non-Small Cell Lung Cancer
The recommended dosage is 15 mg/kg intravenously every 3 weeks in combination with carboplatin and paclitaxel.
Metastatic Renal Cell Carcinoma
The recommended dosage is 10 mg/kg intravenously every 2 weeks in combination with interferon alfa.
Persistent, Recurrent, or Metastatic Cervical Cancer
The recommended dosage is 15 mg/kg intravenously every 3 weeks in combination with paclitaxel and cisplatin or in combination with paclitaxel and topotecan.
Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Stage III or IV Disease Following Initial Surgical Resection
The recommended dosage is 15 mg/kg intravenously every 3 weeks in combination with carboplatin and paclitaxel for up to 6 cycles, followed by Jobevne 15 mg/kg every 3 weeks as a single agent for a total of up to 22 cycles or until disease progression, whichever occurs earlier.
Recurrent Disease
Platinum Resistant
The recommended dosage is 10 mg/kg intravenously every 2 weeks in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan (every week).
The recommended dosage is 15 mg/kg intravenously every 3 weeks in combination with topotecan (every 3 weeks).
Platinum Sensitive
The recommended dosage is 15 mg/kg intravenously every 3 weeks, in combination with carboplatin and paclitaxel for 6 to 8 cycles, followed by Jobevne 15 mg/kg every 3 weeks as a single agent until disease progression.
The recommended dosage is 15 mg/kg intravenously every 3 weeks, in combination with carboplatin and gemcitabine for 6 to 10 cycles, followed by Jobevne 15 mg/kg every 3 weeks as a single agent until disease progression.
Dosage Modifications for Adverse Reactions
Table 1 describes dosage modifications for specific adverse reactions . No dose reductions for Jobevne are recommended.
|
Adverse Reaction |
Severity |
Dosage Modification |
|
Gastrointestinal Perforations and Fistulae. |
|
Discontinue Jobevne |
|
Wound Healing Complications. |
|
Withhold Jobevne until adequate wound healing. The safety of resumption of bevacizumab products after resolution of wound healing complications has not been established |
|
Discontinue Jobevne |
|
|
Hemorrhage. |
|
Discontinue Jobevne |
|
Withhold Jobevne |
|
|
Thromboembolic Events. |
|
Discontinue Jobevne |
|
Discontinue Jobevne |
|
|
Hypertension. |
|
Discontinue Jobevne |
|
Withhold Jobevne until controlled with medical management; resume once controlled |
|
|
Posterior Reversible Encephalopathy Syndrome (PRES). |
|
Discontinue Jobevne |
|
Renal Injury and Proteinuria. |
|
Discontinue Jobevne |
|
Withhold Jobevne until proteinuria less than 2 grams per 24 hours |
|
|
Infusion-Related Reactions. |
|
Discontinue Jobevne |
|
Interrupt infusion; resume at a decreased rate of infusion after symptoms resolve |
|
|
Decrease infusion rate |
|
|
Congestive Heart Failure. |
Any |
Discontinue Jobevne |
Preparation and Administration
Preparation
-
Use appropriate aseptic technique.
-
Use sterile needle and syringe to prepare Jobevne.
-
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard vial if solution is cloudy, discolored or contains particulate matter.
-
Withdraw necessary amount of Jobevne and dilute in a total volume of 100 mL of 0.9% Sodium Chloride Injection, USP. DO NOT ADMINISTER OR MIX WITH DEXTROSE SOLUTION.
-
Discard any unused portion left in a vial, as the product contains no preservatives.
-
Diluted Jobevne solution may be stored at 2°C to 8°C (36°F to 46°F) for up to 8 hours, if not used immediately.
-
No incompatibilities between Jobevne and polyvinylchloride or polyolefin bags have been observed.
Administration
- •
- Administer as an intravenous infusion.
- •
- First infusion: Administer infusion over 90 minutes.
- •
- Subsequent infusions: Administer second infusion over 60 minutes if first infusion is tolerated. Administer all subsequent infusions over 30 minutes if second infusion over 60 minutes is tolerated.
Frequently asked questions
- What are biosimilar drugs and how do they compare to biologics?
- What’s the difference between Eylea, Eylea HD, and Avastin?
- What are biologic drugs and how do they work?
- What biosimilars have been approved in the United States?
- What is the difference between Mvasi and Avastin?
More about Jobevne (bevacizumab)
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: VEGF/VEGFR inhibitors
- Breastfeeding
Patient resources
Other brands
Avastin, Zirabev, Mvasi, Avzivi, ... +2 more
Professional resources
Other brands
Avastin, Zirabev, Mvasi, Avzivi, ... +2 more
Related treatment guides
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Taxol
Taxol (paclitaxel) is used to treat breast cancer, lung cancer, and ovarian cancer. Includes Taxol ...
Carboplatin
Carboplatin is used alone or in combination with other medications to treat ovarian cancer. Learn ...
Pembrolizumab
Pembrolizumab (Keytruda) is a monoclonal antibody cancer medicine used to treat
Methotrexate
Methotrexate is used to treat certain types of cancer of the breast, skin, head and neck, or lung ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
